Rationale and clinical implication of combined chemotherapy with cisplatin and oestrogen in prostate cancer: Primary evidence based on methylation analysis of oestrogen receptor-α

BJU International

Volumn 101, Issue 4, 2008, Pages 485-491

  Moriyama Gonda, Nobuko ^a   Shiina, Hiroaki ^a   Terashima, Masaharu ^a   Satoh, Kazumi ^a   Igawa, Mikio ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Cisplatin; Combination chemotherapy; ER methylation; Oestrogen; Prostate cancer

Indexed keywords

CISPLATIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HIGH MOBILITY GROUP B1 PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN LNCAP; CELL VIABILITY; CHEMOTHERAPY; CONTROLLED STUDY; DNA SEQUENCE; GENETIC TRANSFECTION; GLEASON SCORE; HUMAN; HUMAN CELL; METHYLATION; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CISPLATIN; ESTROGEN RECEPTOR ALPHA; ESTROGENS; HUMANS; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 38549173539     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07256.x     Document Type: Article

References (21)

1. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351 : 1513 20
2. Urakami S, Igawa M, Kikuno N et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002 168 : 2444 50
3. Urakami S, Yoshino T, Kikuno N et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urology 2005 65 : 543 8
4. Kelly WK, Curley T, Slovin S et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001 19 : 44 53
5. Hudes G, Einhorn L, Ross E et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer. A Hoosier Oncology Group and Fox Chase Network Phase III Trial. J Clin Oncol 1999 17 : 3160 6
6. Dijt FJ, Fichtinger-Schepman AM, Berends F, Reedijk J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 1988 48 : 6058 62
7. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts Chem Rev 1999 99 : 2467 98
8. He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci USA 2000 97 : 5768 72
9. Li L, Liu X, Glassman AB et al. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res 1997 57 : 1487 94
10. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specially inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994 91 : 10394 8
11. Boonyaratanakornkit V, Melvin V, Prendergast P et al. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol 1998 18 : 4471 87
12. The Japanese Urological Association and the Japanese Society of Pathology. General Rules for Clinical and Pathological Studies on Prostate Cancer, 3rd edn. Tokyo : Kanahara-Shuppan, 2001
13. Shigeno K, Igawa M, Shiina H, Kishi H, Urakami S. Transrectal colour Doppler ultrasonography for quantifying angiogenesis in prostate cancer. BJU Int 2003 91 : 223 6
14. Li LC, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 2000 60 : 702 6
15. Thomas JO, Travers AA. HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Sci 2001 26 : 167 74
16. Muller S, Scaffidi P, Degryse B et al. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 2001 20 : 4337 40
17. Krynetski EY, Krynetskaia NF, Bianchi ME, Evans WE. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 2003 63 : 100 6
18. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-{alpha} mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005 12 : 851 66
19. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000 60 : 3175 82
20. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006 66 : 7490 501
21. Li LC, Shiina H, Deguchi M et al. Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun 2004 321 : 455 61